The treatment of patients with initial isoniazid resistance
|
|
- Silvester Darrell Black
- 6 years ago
- Views:
Transcription
1 The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011
2 Outline Background Monotherapy with isoniazid or rifampicin Bacterial populations during treatment Isoniazid alone in the continuation phase Outcomes of treating patients with initial isoniazid resistance The effect of adding drugs in the continuation phase Conclusions
3 Abbreviations Isoniazid: INH / H Ethambutol: EMB / E Rifampicin: RIF / R Streptomycin: STR / S Pyrazinamide: PZA / Z
4 Background Estimated 14% of incident TB cases with INH resistance outside Eastern Europe 45% in Eastern Europe (Jenkins, PLoS One, 2011) 2009 WHO treatment guidelines recommend adding EMB in the continuation phase in areas with high levels of INH resistance: 2ERHZ/4HR 2ERHZ/4HRE How do outcomes compare in those with initial resistance to INH? What are the risks of further acquired RIF resistance during standard therapy?
5 Monotherapy with isoniazid or rifampicin Total Cultures with resistance at month: Patients with resistant strains INH (daily for 12m) % 56% 76% 97% 47% at 12 mo. RIF (daily for 60 days % 94% 100% - 33% at 3 mo. 1 Madras TB Chemotherapy Centre, Bull WHO Nitti V, Antibiot Chemother
6 Bacterial populations during treatment A population of at least: 3.5 x 10 6 is needed for a single mutant resistant to INH to occur 3.1 x 10 8 is required for a mutant resistant to RIF to occur (David HL, Appl. Microbiol., 1970)
7 Bacterial populations during treatment Example from OFLOTUB Phase II Rustomjee R et al., 2008 Before treatment At 8 weeks Patients Mean No patient had a residual bacterial population at 8 weeks sufficiently large to contain RIF resistant Max. SD mutants. Content of viable M. tuberculosis before and after an initial 2-month phase of 4-drug therapy. log CFU/ml sputum
8 Isoniazid alone in the continuation phase In a randomised controlled trial in Tanzania (T/BMRC, 1996), two 7 month regimens were compared: HRZ (6 weeks) / H (24 weeks) HRZ (30 weeks) Of the 266 patients (135 H; 131 H(RZ)): Only 1 patient in each series had a positive culture at month 7 with the emergence of INH resistance. Thus, failure and emergence of resistance was a rare phenomenon despite a shorter than usual intensive phase.
9 Outcomes of treating patients with initial isoniazid resistance Review of randomised trials including patients with initial INH resistance Illustrative, not systematic BMRC trials and IUATLD Studies A and C Broadly similar trial design and conduct, so high level of homogeneity 9 trials, 13 regimens
10 Outcomes of treating patients with initial isoniazid resistance All six month regimens: 4-drug intensive phase Daily or 3-weekly continuation phase of RH Unfavourable outcome is bacteriologically confirmed failure or relapse
11 Outcomes of treating patients with initial isoniazid resistance Study Regimen INH susceptible INH resistant Assessed Unfav (N) Assessed Unfav (N) Algeria 1 2HRZE/4HR Algeria 2 2SHRZ/4HR East Africa 5 2SHRZ/4HR Singapore 1 2SHRZ/4HR Singapore 2 2SHRZ/4H Singapore 2 1SHRZ/5H Singapore 3 2SHRZ(C)/4H Singapore 3 2SHRZ(S)/4H Singapore 3 1SHRZ(C)/5H Singapore 3 1SHRZ(S)/5H HK Rifapentine 2SHRZ/4H IUATLD Study A 2EHRZ/4HR IUATLD Study C 2EHR/4HR (5%) (9%) Total (4%) (7%)
12 Outcomes of treating patients with initial isoniazid resistance Unfavourable outcomes: INH-susceptible: 100 (4%) INH-resistant: 15 (7%) p=0.083 (Mantel-Haenszel test, stratified by trial) Acquisition of RIF resistance: INH-susceptible: 3 (6%) of 51 INH-resistant: 2 (22%) of 9 p=0.105 (Mantel-Haenszel test) High proportion of patients from IUATLD Study C, but no evidence of heterogeneity between trials (p=0.31)
13 Sub-group analysis by HIV status HIV Status HIV Negative Study INH susceptible INH resistant Assessed Unfav (N) Assessed Unfav (N) IUATLD Study A (4%) 15 0 (0%) IUATLD Study C (5%) (8%) Overall (5%) (7%) Acquired RIF resistance 0 (0%) / 26 1 (17%) / 6 HIV Positive IUATLD Study A 5 0 (0%) 3 0 (0%) IUATLD Study C 60 9 (15%) 9 2 (22%) Overall 65 9 (14%) 12 2 (17%) Acquired RIF resistance 0 (0%) / 2 0 (0%) / 0 On the limited evidence, HIV infection can only partly be responsible for the apparent increased risk of an unfavourable result in those with initial INH resistance.
14 Sub-group analysis by type of unfavourable outcome Unfavourable outcomes that were treatment failures: MRC studies: 2 (5%) of 44 Study A: 5 (10%) of 52 Study C: 23 (20%) of 115 Increase in Study C due to: Less frequent bacteriology About half failures/relapses not based on robust bacteriology
15 The effect of adding drugs in the continuation phase Study Regimen INH susceptible Assessed Unfav (N) Assessed INH resistant Unfav (N) Singapore 1 2SHRZ/4HRZ Hong Kong 4 2S 3 H 3 Z 3 / 4H 3 S 3 (Z 3 ) Hong Kong 3 6H 3 S 3 Z Hong Kong 3 6H 3 E 3 Z Hong Kong 3 6HREZ Hong Kong 3 6H 3 E 3 S 3 Z Total (2%) (7%) Acquired RIF resistance 2 (6%) / 31 2 (25%) / 8
16 Conclusions 1. The bacterial population is likely too small after 2- months of treatment for RIF-resistant mutants to exist Unless bacterial re-growth is allowed to occur in the continuation phase Mutants resistant to INH are ~100 times more prevalent than those resistant to RIF. 2. The favourable rate in patients with initial INH resistance is not much lower than those without initial INH resistance: 93% compared with 96%. 3. This is strengthened by the Tanzanian trial showing that the development of resistance was very rare with INH alone in the continuation phase.
17 Conclusions 4. The addition of PZA, STR or EMB or a combination to the continuation phase did not reduce the occurrence of an unfavourable outcome or the proportion of failure strains that were resistant to RIF. 5. However, there could be a role for PZA in the continuation phase as there is limited evidence that it could prevent treatment failure. 6. Randomised controlled trials are needed to indentify the best treatment for patients with mono- and poly-drug resistance.
18 References Mitchison DA, Phillips PPJ, Jindani A, Lienhardt C, Nunn AJ. Outcomes of treatment with a rifampicin/isoniazid continuation in patients with organisms initially resistant to isoniazid [Submitted] Jenkins HE, Zignol M, Cohen T. Quantifying the burden and trends of isoniazid resistant tuberculosis, PLoS One. 2011; 6(7): e Madras Tuberculosis Chemotherapy Centre. A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India. Bull WHO. 1960; 23: David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970; 20(5): Nitti V. Experimental and clinical studies on the antituberculous activity of rifampicin alone or combined with other drugs. Antibiot Chemother. 1970; 16: Tanzania/British Medical Research Council. A controlled trial of a 4-weekly supplement of rifampicin, pyrazinamide and streptomycin in the continuation phase of a 7-month daily chemotherapy regimen for pulmonary tuberculosis. Tanzania/British Medical Research Council Collaborative Investigation. S Afr Med J. 1996; 86(8): Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008; 12: (11).
Improving Translation in TB Drug Development Through Quantitative Modeling. CPTR Workshop 2016, Washington DC
Improving Translation in TB Drug Development Through Quantitative Modeling Lessons from Recent Phase III TB Trials CPTR Workshop 2016, Washington DC Christian Lienhardt Global TB Programme WHO, Geneva,
More informationGlobal epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos
Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe
More informationTreatment of Tuberculosis, 2017
Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,
More informationTreatment of Tuberculosis. Dr Sarabjit Chadha The Union
Treatment of Tuberculosis Dr Sarabjit Chadha The Union History of treatment of TB. Believed to be as old as mankind Spinal TB has been diagnosed in Egyptian mummies dating 2400 BC Egyptian medical treatise
More informationNEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY
NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence
More informationManagement of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore
Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis
More informationMultidrug-resistant tuberculosis in children
Multidrug-resistant tuberculosis in children James Seddon Clinical Lecturer Imperial College London UCL-TB and LSHTM TB Centre World TB Day 2015 24th March 2015 Outline Burden Recent studies Preventive
More informationIssues in TB Drug Development for Sensitive Disease - Clinical Development
Issues in TB Drug Development for Sensitive Disease - Clinical Development GATB Open Forum New Delhi, 5-6 May 2008 Christian Lienhardt, MD, DTM, MSc, PhD IRD, Paris, France & International Union Against
More informationTable S1: Summary of randomized trials pooled for analysis of isoniazid resistance
Table S1: Summary of randomized trials pooled for analysis of isoniazid resistance Year study began Total treated (N) Male Age of Outcomes measured Ref. Author Country (%) Participants Failure Relapse
More informationGlobal Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics
Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948
More informationWHO treatment guidelines for isoniazidresistant
WHO treatment guidelines for isoniazidresistant tuberculosis Online Annexes: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis WHO treatment guidelines for isoniazid-resistant
More informationPHARMACOTHERAPY OF TUBERCULOSIS MANAGEMENT
PHARMACOTHERAPY OF TUBERCULOSIS MANAGEMENT Rahela Ambaras Khan BPharm (USM), MPharm (Clin.)(UKM), BCPS(US) PhD Student Faculty of Medicine University Malaya OUTLINE Introduction to Tuberculosis Management
More informationMULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic
MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin
More informationPrinciples and practice of treating drug-sensitive TB
Principles and practice of treating drug-sensitive TB Brian Eley Paediatric Infectious Diseases Unit Red Cross War Memorial Children s Hospital Department of Paediatrics and Child Health University of
More informationAuthor s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis
Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis Authors: Phan Thai (phanvuongkhacthai@yahoo.com) Dang Ha
More informationTreatment of Tuberculosis
Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict
More informationRecognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016
Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the
More informationTreatment of Tuberculosis
TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features
More informationEtiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition
Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis
More informationDevelopment of New Regimens for Tuberculosis Zhenkun Ma, Ph.D.
Development of New Regimens for Tuberculosis Chief Scientific Officer Global Alliance for TB Drug Development 40 Wall Street, 24th Floor New York, NY 10005 USA 1 Outline What are the unmet needs in TB
More informationSputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation?
Journal of Antimicrobial Chemotherapy (27) 59, 794 798 doi:.93/jac/dkm25 Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? Jesús
More informationMarcos Burgos, MD has the following disclosures to make:
Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures
More informationClinical spectrum and standard treatment of tuberculosis
Clinical spectrum and standard treatment of tuberculosis Graham Bothamley Homerton University Hospital, London, UK 2 nd European Advanced Course in Clinical Tuberculosis 1 Plan of talk Why is there a clinical
More informationTBTC research update: are we ready for 3 month treatment? 2009 TBTC Recompetition. NTCA presentation outline
TBTC research update: are we ready for 3 month treatment? Stefan Goldberg, MD Project officer, TBTC Studies 27, 28, 29 Tuberculosis Trials Consortium (TBTC) CDC Division of TB Elimination NTCA breakout
More informationThe Role of Rifampin for the Treatment of Latent TB Infection. Introduction. Introduction
The Role of Rifampin for the Treatment of Latent TB Infection March 26, 2008 Alfred A. Lardizabal, MD Associate Professor of Medicine New Jersey Medical School Global Tuberculosis institute Treatment of
More informationAuthors Schluger, N; Karunakara, U; Lienhardt, C; Nyirenda, T E; Chaisson, R
MSF Field Research Building clinical trials capacity for tuberculosis drugs in highburden countries Item type Article Authors Schluger, N; Karunakara, U; Lienhardt, C; Nyirenda, T E; Chaisson, R Citation
More informationThe shorter regimen for MDR-TB: evidence and pitfalls
The shorter regimen for MDR-TB: evidence and pitfalls Helen Cox 10 November 2017 What is the shortened regimen? Current conventional regimen (SA): Intensive Phase (at least 6 months): PZA / (EMB) / Kana
More informationTuberculosis Intensive November 17 20, 2015 San Antonio, TX
Treatment of Tuberculosis Elizabeth S. Guy, MD November 17, 2015 Tuberculosis Intensive November 17 20, 2015 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Elizabeth S. Guy, MD has the following disclosures
More informationPredicting outcomes and drug resistance with standardised treatment of active tuberculosis
Eur Respir J 21; 36: 87 877 DOI: 1.1183/931936.15179 CopyrightßERS 21 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis O. Oxlade*,#, K. Schwartzman*,#, M. Pai*,#,
More informationLimited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
Phillips et al. BMC Medicine (2016) 14:19 DOI 10.1186/s12916-016-0565-y World TB Day RESEARCH ARTICLE Limited role of culture conversion for decision-making in individual patient care and for advancing
More informationPZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data. Tawanda Gumbo
PZA: A New Look Based on RNASeq, the Hollow Fiber System, and Patient Level Data Tawanda Gumbo Office of Global Health University of Texas Southwestern Medical Center, Dallas, Texas The team: this work
More informationTHE EFFICACY OF SHORT-COURSE CHEMOTHERAPY FOR TUBERCULOSIS1
Bull Pan Am Health Organ 14(2); 1980 THE EFFICACY OF SHORT-COURSE CHEMOTHERAPY FOR TUBERCULOSIS1 Jacques Grosset * Potentially, shortened courses of drug chemotherapy for tuberculosis have obvious advantages
More informationNewer anti-tb drugs and regimens. DM Seminar
Newer anti-tb drugs and regimens DM Seminar 31-10-14 Why are newer drugs/regimens needed? Problems with current drugs/regimens Drug resistance Drug interaction of anti-tubercular drugs with ART Long duration
More informationTreatment of Active Tuberculosis
Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest
More informationSirturo: a new treatment against multidrug resistant tuberculosis
Sirturo: a new treatment against multidrug resistant tuberculosis TB is an on-going problem WHO estimated incidence of new TB cases 2009 Global Tuberculosis Control: WHO report 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html
More informationShort Course Treatment for MDR TB
Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize
More informationWhat are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis
Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ thoraxjnl-2015-208262). For numbered affiliations see end of article. Correspondence to
More informationChemotherapy of tuberculosis in Hong Kong: a consensus statement
Chemotherapy of tuberculosis in Hong Kong MEDICAL PRACTICE Chemotherapy of tuberculosis in Hong Kong: a consensus statement The Tuberculosis Control Coordinating Committee of the Hong Kong Department of
More informationOutline 8/2/2013. PK/PD PK/PD first-line drug กก PK/PD กก
Pharmacokinetic and pharmacodynamic of anti- tuberculosis drugs Outline PK/PD PK/PD first-line drug กก PK/PD กก Concentration vs time in tissue and other body fluids Pharmacologic or toxicologic effect
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment
More informationPrinciple of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos
Principle of Tuberculosis Control CHIANG Chen-Yuan MD, MPH, DrPhilos Estimated global tuberculosis burden 2015 an estimated 10.4 million incident cases of TB (range, 8.7 million 12.2 million) 142 cases
More informationRECENT ADVANCES OF TUBERCULOSIS MANAGEMENT. Qais Abdulmajeed Haddad Consultant ID & IC Security Forces Hospital Program Riyadh - Saudi Arabia
RECENT ADVANCES OF TUBERCULOSIS MANAGEMENT Qais Abdulmajeed Haddad Consultant ID & IC Security Forces Hospital Program Riyadh - Saudi Arabia RECENT ADVANCES OF TUBERCULOSIS MANAGEMENT History Epidemiology
More informationMoving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012
Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict
More informationDiagnosis of drug resistant TB
Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million
More informationElizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.
The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,
More informationAbstract. n engl j med 371;17 nejm.org october 23,
The new england journal of medicine established in 1812 october 23, 2014 vol. 371 no. 17 Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis Stephen H. Gillespie, M.D., D.Sc., Angela
More informationTherapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation
Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation Randall Reves, MD, MSc TB Consultant Professor of Medicine and
More informationTitle: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.
Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant
More informationThe Diagnosis and Therapy of Tuberculosis During the Past 100 Years
Centennial Review The Diagnosis and Therapy of Tuberculosis During the Past 100 Years Denis A. Mitchison Medical Microbiology, Department of Cellular and Molecular Medicine, St. George s Hospital Medical
More informationACCESS TO MEDICINES. Update on tuberculosis field activities
ACCESS TO MEDICINES Update on tuberculosis field activities Update on clinical activities 1/3 Latent TB Prevent study (S26) main study (8053 patients) PK substudy construction of a POPPK model Paediatric
More informationMycobacterium tuberculosis
Mycobacterium tuberculosis Mycobacterium tuberculosis Ø small, aerobic, nonmotile bacteria Ø Gram-positive bacillus Ø can survive in a dry state for weeks Ø grow only within the cells of a host organism
More informationTB ReFLECT Meta-Analysis of Fluoroquinolone-Containing Regimens for the Treatment of Drug-Susceptible TB
TB ReFLECT Meta-Analysis of Fluoroquinolone-Containing Regimens for the Treatment of Drug-Susceptible TB Rada Savic, PhD Medical Consultant Meeting San Antonio, TX November 29-30, 2018 1 EXCELLENCE EXPERTISE
More informationMANAGEMENT OF DILI in TB/HIV coinfected patients. Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo
MANAGEMENT OF DILI in TB/HIV coinfected patients Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo ANTI-TB drugs Groups Drugs Group 1: First-line oral drugs Ethambutol (Emb) Pyrazinamide(PZA) Isoniazid (INH)
More informationRapid Diagnosis and Detection of Drug Resistance in Tuberculosis
Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries
More informationNew TB Medications. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention New TB Medications Neha Shah MD MPH Field Medical Officer Tuberculosis Control Branch California Department of Public Health Centers
More informationDrug Interactions Lisa Armitige, MD, PhD November 17, 2010
Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010 Drug Interactions Lisa Armitige, MD, PhD November 17, 2010 Drug Interactions Lisa Y. Armitige, M.D., Ph.D. Medical Consultant
More informationCertainty assessment of patients Effect Certainty Importance. a standardised 9 month shorter MDR-TB regimen. e f
Author(s): STREAM Stage 1 Trial investigators reported for the Guideline Development Group for the WHO treatment guidelines on MDR/RR-TB, 2018 update (6 July 2018) - FINAL RESULTS Question: PICO 1. In
More informationShorter TB regimens What is in de pipeline? Martin Boeree, Associate Professor Radboudumc, Nijmegen, the Netherlands Tuesday, 23 September, 2014
Shorter TB regimens What is in de pipeline? Martin Boeree, Associate Professor Radboudumc, Nijmegen, the Netherlands Tuesday, 23 September, 2014 Disclosures Clinical trials and studies funded by EDCTP,
More informationTUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION In the WHO Western Pacific Region 2002 Report
TUBERCULOSIS CONTROL IN THE WHO WESTERN PACIFIC REGION 2000 Tuberculosis Control In the WHO Western Pacific Region 2002 Report World Health Organization Office for the Western Pacific Region iii TUBERCULOSIS
More informationMycobacterium tuberculosis
Mycobacterium tuberculosis Mycobacterium tuberculosis Ø aerobic Gram-positive bacillus Ø grow in the cell of host organism Ø the pathogen causes tuberculosis Ø asymptomatic and latent infections Ø can
More informationManaging Complex TB Cases Diana M. Nilsen, MD, RN
Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private
More informationThe Epidemiology of Tuberculosis in Minnesota,
The Epidemiology of Tuberculosis in Minnesota, 2011 2015 Minnesota Department of Health Tuberculosis Prevention and Control Program (651) 201-5414 Tuberculosis surveillance data for Minnesota are available
More informationTB Intensive San Antonio, Texas
TB Intensive San Antonio, Texas April 6-8, 2011 TB Disease: ATS/CDC/IDSA Guidelines Barbara Seaworth, MD Thursday April 7, 2011 Barbara Seaworth, MD has the following disclosures to make: Has received
More informationPharmacokinetics and doses of antituberculosis drugs in children
Pharmacokinetics and doses of antituberculosis drugs in children HS Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health Stellenbosch University Declarations I have no conflict of interest
More informationEvidence review for Intermittent therapy for drug-susceptible TB: Questions addressed: intermittent therapy
Evidence review for Intermittent therapy for drug-susceptible TB: Dr. Dick Menzies Montreal Chest Institute, McGill University Montreal, Canada Questions addressed: intermittent therapy 1: Does intermittent
More informationCURRICULUM VITAE Research Institute of Tuberculosis. Tokyo/ Japan
Full name (print): CHAROEN CHUCHOTTAWORN Date of update: 20/02/2017 Present position: Senior Medical Expert, Advisory Level Business address: Department of Respiratory Medicine Central Chest Institute
More informationDrug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER
Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility
More informationMDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT
TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words
More informationDiagnosis and Treatment of Tuberculosis, 2011
Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is
More informationTreatment of INH Resistant-TB An aggregate data, and an Individual Patient Data (IPD) meta-analyses
Treatment of INH Resistant-TB An aggregate data, and an Individual Patient Data (IPD) meta-analyses Dick Menzies Montreal Chest Institute, McGill International TB Centre NAR Meeting Chicago, March 1-3,
More informationI have been asked to review in 45 minutes all of
The Chemotherapy of Pulmonary Tuberculosis: A Review Wallace Fox, M.D. I have been asked to review in 45 minutes all of the chemotherapy of tuberculosis! Of necessity I shall be brief and I shall therefore
More informationProblems, progress and evaluation of agents in clinical development ACCEPTED. Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
AAC Accepts, published online ahead of print on 15 December 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00749-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationMultiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health
Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten
More informationTB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS
TB-CHAMP A PHASE 3 CLUSTER RANDOMIZED TRIAL FOR PREVENTION OF TB IN CHILD HOUSEHOLD CONTACTS ANNEKE C. HESSELING RESIST TB WEBINAR 20 APRIL 2017 DESMOND TUTU TB CENTRE PROFESSOR IN PAEDIATRICS AND CHILD
More informationCHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY
CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!
More informationTreatment of Tuberculosis
TB Intensive Tyler, Texas June 1-3, 2009 Treatment of Tuberculosis Barbara Seaworth, MD June 3, 2009 Treatment of Tuberculosis Barbara J Seaworth MD Medical Director Heartland National TB Center 1 Purpose
More informationTuberculosis in Greece: bacteriologically confirmed cases and anti-tuberculosis drug resistance,
Surveillance and outbreak reports Tuberculosis in Greece: bacteriologically confirmed cases and anti-tuberculosis drug resistance, 1995-2009 D Papaventsis (dpapaventsis@yahoo.gr) 1, S Nikolaou 1, S Karabela
More informationHot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs
Slide 1 Hot Issues in Tuberculosis: Treatment of Latent TB Infection and New TB Drugs Constance A. Benson, M.D. Professor of Medicine Division of Infectious Diseases University of California, San Diego
More informationTuberculosis: update 2013
Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference
More informationTB Nurse Case Management San Antonio, Texas April 9-11, 2013
TB Nurse Case Management San Antonio, Texas April 9-11, 2013 TB / Dose Counting Rachel Munoz, RN. TB Nurse Case Manager/Nurse Consultant Austin/Travis County Health Department April 10, 2013 Rachel Munoz,
More informationTB Updates for the Physician Rochester, Minnesota June 19, 2009
TB Updates for the Physician Rochester, Minnesota June 19, 2009 Recent Findings & Activities of the Tuberculosis Trials Consortium (TBTC) Bill Burman Denver TBTC Unit & Denver Public Health Recent findings
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based
More informationDrug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye
Director of Health Information World Health Organization Geneva 1 1. Why TB patients are treated with drugs 2 Natural history and control of TB Fast 5/1 Slow 5/1 Uninfected Latent Active 1 1 infection/case
More informationFundamentals of Tuberculosis (TB)
TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported
More informationGuidelines for treatment of drug-susceptible tuberculosis and patient care
TREATMENT OF TUBERCULOSIS Guidelines for treatment of drug-susceptible tuberculosis and patient care 2017 UPDATE Annex 4 EVIDENCE-TO-DECISION TABLES TREATMENT OF TUBERCULOSIS Guidelines for treatment
More informationNATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis
NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis Patients registered during quarter* of 20 Name of area No.# Name of the Reporter Signature:
More informationPharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs in patients with tuberculosis Julie B Prahl, MD, PhD International Reference Laboratory of Mycobacteriology, Diagnostics and Infection Control
More informationSurgery for MDR/XDR Tuberculosis
Surgery for MDR/XDR Tuberculosis John D. Mitchell, M.D. Davis Endowed Chair in Thoracic Surgery Professor and Chief, General Thoracic Surgery Department of Surgery University of Colorado School of Medicine
More informationDRUG RESISTANCE IN TUBERCULOSIS
DRUG RESISTANCE IN TUBERCULOSIS INTRODUCTION Up to 50 million people may be infected with drug-resistant resistant TB.* Hot zones of MDR-TB such as Russia, Latvia, Estonia, Argentina and the Dominican
More informationOvercoming the Challenges in Access to TB Drugs for Children
Overcoming the Challenges in Access to TB Drugs for Children Gregory L. Kearns, PharmD, PhD Professor of Pediatrics and Pharmacology, University of Missouri Marion Merrell Dow / Missouri Chair in Pediatric
More informationLet s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year
A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year Madhukar Pai, MD, PhD Author and Series Editor Camilla Rodrigues, MD co-author Abstract Most individuals who get exposed
More informationTuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012
Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally
More informationDiagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011
TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:
More informationStudy of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan
Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza
More informationWHO treatment guidelines for isoniazid-resistant tuberculosis
Frequently asked questions on the WHO treatment guidelines for isoniazid-resistant tuberculosis Version: 24 April 2018 The advice in this document has been prepared by the Global TB Programme of the World
More informationchildhood tuberculosis
Archives of Disease in Childhood, 1989, 64, 1004-1012 Management and outcome of chemotherapy for childhood tuberculosis MEDICAL RESEARCH COUNCIL TUBERCULOSIS AND CHEST DISEASES UNIT SUMMARY The management
More informationFixed-dose combination antituberculosis therapy: a systematic review and meta-analysis
ORIGINAL ARTICLE TUBERCULOSIS Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis Amr S. Albanna 1, Benjamin M. Smith 1, Deanna Cowan 2 and Dick Menzies 1 Affiliations:
More informationHA Convention 2016 : Special Topic Session 3 May 2016
HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis
More informationImpact of the interaction of R with rifampin on the. treatment of tuberculosis studied in the mouse model ACCEPTED
AAC Accepts, published online ahead of print on 21 July 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00566-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationMulti-drug Resistant Tuberculosis in Rajshahi District
TAJ December 2005; Volume 18 Number 2 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Original Article Multi-drug Resistant Tuberculosis in Rajshahi District M Wasim Hussain, 1 M Azizul
More information